Autolus Therapeutics plc (AUTL) Spending and interest coverage
- R&D / revenue · 12 months: Value 95.95%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value (m); Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value -5.92×; Formula and calculation Operating income ÷ reported interest expense..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 95.95% | Research and development expense / revenue. Period ending 2026-06-30. $112.63M ÷ $117.39M × 100 ≈ 95.95% |
| Stock-based compensation / revenue · 12 months | (m) | Share-based compensation / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Interest coverage · 12 months | -5.92× | Operating income ÷ reported interest expense. $-247.44M ÷ $41.81M ≈ -5.92× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 112.63M USD | Research and Development Expense |
| Revenue | 117.39M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | (m) | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -247.44M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | 41.81M USD | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: Reported. Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $112.63M | $117.39M | (m) | $-247.44M | $41.81M | 95.95% | (m) | -5.92× | Reported |
| 2026-03-31 | $112.17M | $92.62M | (m) | $-264.82M | $37.65M | 121.10% | (m) | -7.03× | Reported |
| 2025-12-31 | $117.69M | $75.39M | (m) | $-270.54M | $36.67M | 156.11% | (m) | -7.38× | Reported |
| 2025-09-30 | $112.89M | $51.13M | (m) | $-273.94M | $-17.00M | 220.79% | (m) | (m) | Reported |
| 2025-06-30 | $125.32M | $29.93M | (m) | $-270.20M | $-16.84M | 418.64% | (m) | (m) | Reported |
| 2025-03-31 | $134.50M | $9.01M | (m) | $-267.91M | $168.00K | 1492.61% | (m) | -1594.70× | Reported |
| 2024-12-31 | $138.44M | $10.12M | (m) | $-241.43M | $9.29M | 1367.94% | (m) | -25.98× | Reported |
| 2024-09-30 | $145.15M | (m) | (m) | $-218.83M | $70.26M | (m) | (m) | -3.11× | Reported |
| 2024-06-30 | $137.14M | (m) | (m) | $-193.86M | $64.58M | (m) | (m) | -3.00× | Reported |
| 2024-03-31 | $133.76M | (m) | (m) | $-179.31M | $59.43M | (m) | (m) | -3.02× | Reported |
| 2023-12-31 | $130.48M | (m) | (m) | $-179.70M | $45.07M | (m) | (m) | -3.99× | Reported |
| 2023-09-30 | $137.51M | (m) | (m) | $-175.10M | $18.40M | (m) | (m) | -9.52× | Reported |
| 2023-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | $116.38M | (m) | (m) | $-146.37M | $12.02M | (m) | (m) | -12.18× | Reported |
| 2022-12-31 | $141.99M | (m) | (m) | $-168.05M | $8.90M | (m) | (m) | -18.87× | Reported |
| 2022-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $108.47M | (m) | (m) | $-137.36M | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $134.79M | (m) | (m) | $-165.00M | $1.10M | (m) | (m) | -149.32× | Reported |
| 2021-03-31 | $134.33M | (m) | (m) | $-169.45M | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $134.89M | (m) | (m) | $-168.15M | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | $125.53M | (m) | (m) | $-163.90M | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | $119.30M | $1.24M | (m) | $-156.81M | (m) | 9643.90% | (m) | (m) | (m) |
| 2020-03-31 | $114.14M | $1.28M | (m) | $-154.47M | (m) | 8903.28% | (m) | (m) | (m) |
| 2019-12-31 | $105.42M | $2.91M | (m) | $-146.06M | (m) | 3625.10% | (m) | (m) | (m) |
| 2019-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | $59.24M | $3.01M | (m) | (m) | (m) | 1968.01% | (m) | (m) | (m) |
| 2018-12-31 | $48.30M | $1.47M | (m) | (m) | (m) | 3281.18% | (m) | (m) | (m) |
| 2018-09-30 | $36.15M | $1.41M | (m) | (m) | (m) | 2569.30% | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-09-30 | $16.01M | $1.69M | (m) | (m) | (m) | 945.78% | (m) | (m) | (m) |
| 2016-09-30 | $10.44M | $1.21M | (m) | (m) | (m) | 861.06% | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 |